Top in hem/onc: Harassment among female gynecologic oncologists, Keytruda approval
Last week, survey results revealed gender discrimination in the gynecologic oncology workforce. Female practitioners reported high rates of workplace bullying and microaggressions. It was the top story in hematology/oncology.
Another top story was about the FDA approval of Keytruda (pembrolizumab, Merck) for esophageal and gastroesophageal carcinoma. The approval was partly based on data from the multicenter, randomized KEYNOTE–590 trial.
Read these and more top stories in hematology/oncology below:
Survey: Most female gynecologic oncologists have faced workplace bullying, harassment
Most female gynecologic oncologists who responded to an internet-based survey reported having experienced workplace bullying, according to a presentation at the virtual Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. Read more.
FDA approves Keytruda for esophageal, gastroesophageal carcinoma
The FDA approved pembrolizumab in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with locally advanced or metastatic esophageal or gastroesophageal carcinoma. Read more.
Racial disparities in cancer care ‘don’t go away in survivorship’
Having cleared a major hurdle by completing active treatment, cancer survivors often find themselves unprepared for the ongoing challenges they face during survivorship. Read more.
Preterm birth risk higher among women with early cervical cancer
Women with early cervical cancer who conceived at least 3 months after fertility-sparing surgery had a high live birth rate, according to results presented at the virtual Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. Read more.
José Baselga, head of oncology R&D for AstraZeneca and ‘true change-maker,’ dies at 61
Prominent cancer researcher José Baselga, MD, PhD, FASCO, who served as head of oncology research and development for AstraZeneca, has died at age 61 years, the company announced in a press release. Read more.